A Look At Metis TechBio (SEHK:7666) Valuation After Recent Share Price Weakness

Metis TechBio: What the Latest Trading Move Tells You

Metis TechBio (SEHK:7666) recently caught investor attention after the stock fell 14% in the latest session, prompting fresh interest in how this AI-focused nanomaterials business is currently being valued.

See our latest analysis for Metis TechBio.

The sharp 1-day share price return of down 14.03% at a latest share price of HK$21.7 sits alongside a year-to-date share price return of down 8.82%. This suggests recent momentum has cooled after earlier trading interest in this newly listed AI nanomaterials business.

If you are looking beyond Metis TechBio for other potential AI related opportunities, it could be worth scanning 62 profitable AI stocks that aren't just burning cash as a starting point for further research.

So with the stock down 14.03% in a day and 8.82% so far this year, is this sharp reset hinting at an undervalued AI nanomaterials business, or is the market simply adjusting to reflect all the growth already expected?

Preferred Price-to-Book of 20.9x: Is It Justified?

Looking at valuation, Metis TechBio is trading on a P/B of 20.9x, which sets a high bar compared with both its Hong Kong biotech peers and a closer peer group.

The P/B ratio compares the company’s market value with its book value, which is effectively the net assets on the balance sheet. For an early stage, research focused business that is still loss making, investors often look to P/B when earnings are not yet positive.

Metis TechBio reported revenue of CN¥105.0m and a net loss of CN¥391.8m, and its return on equity is currently negative at 37.65% in decline, so the high P/B implies the market is paying a premium despite the absence of profits. With a value score of 1 out of 6 and no DCF fair value available, the current price level appears to be baking in substantial expectations that are not yet visible in the reported figures.

Compared with the wider Hong Kong biotechs industry average P/B of 4.4x, Metis TechBio’s 20.9x multiple is almost five times higher, which is a strong premium. Against a tighter peer set, where the average P/B is 77.9x, Metis TechBio screens as cheaper on this single metric, but that still leaves the stock valued far above the broader sector.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Preferred multiple of Price-to-Book of 20.9x (OVERVALUED).

However, the company is still loss making with a CN¥391.8m net loss and heavy expectations embedded in a 20.9x P/B, so sentiment could shift quickly.

Find out about the key risks to this Metis TechBio narrative.

Next Steps

Given this mix of pressure on valuation and interest in the AI theme, it makes sense to move quickly and form your own view. To balance both sides of the argument, take a closer look at the 1 key reward and 1 important warning sign

Looking for more investment ideas?

If Metis TechBio is on your radar, it is worth lining it up alongside other opportunities so you can see where it truly stands.

• Spot potential bargains trading below what their fundamentals suggest by scanning the 233 high quality undervalued stocks.
• Prioritise resilience and sleep a little easier at night by reviewing companies in the 307 resilient stocks with low risk scores.
• Hunt for future standouts before they are widely followed by checking the screener containing 548 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com